Abstract: Disclosed in the present invention are a recombinant herpes zoster vaccine composition and an application thereof. Compared with other combinations of antigens and adjuvants, the novel vaccine composition provided by the present invention has a more beneficial immune effect.
Abstract: A peptide that specifically binds to norovirus, which is useful for detection and infection control of norovirus is provided. A norovirus-binding peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 327.
Abstract: The present invention relates to: a porcine epidemic diarrhea (PED) virus protein comprising an amino acid sequence represented by SEQ ID NO:5; a vaccine composition comprising same; and the like.
Abstract: The present disclosure is directed to compositions and methods useful for treating, as well as vaccinating against, viral infections, including coronavirus infections.
Type:
Grant
Filed:
September 20, 2021
Date of Patent:
July 15, 2025
Assignee:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: Disclosed herein are methods and compositions for identifying and/or treating subjects having or likely to have amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD). Antibodies specific for one or more di-amino acid repeat-containing proteins are also provided herein.
Type:
Grant
Filed:
May 20, 2024
Date of Patent:
July 15, 2025
Assignee:
University of Florida Research Foundation, Incorporated
Abstract: Methods of inhibiting or reducing tumor growth are disclosed. A composition containing at least one selected oncolytic virus is administered within a tumor of a patient. The virus kills cancerous cells and induces a systemic and lasting anti-tumor immunity that is also compatible with other cancer treatments. Also disclosed are methods of creating synthetic viruses for targeting cancerous tumors.
Type:
Grant
Filed:
December 6, 2021
Date of Patent:
July 15, 2025
Assignee:
SATOR THERAPEUTICS
Inventors:
Peter M. Chumakov, Anastasia V. Lipatova, Stepan P. Chumakov, Natalia D. Tararova, Stephen A. Charles, Anton A. Komar
Abstract: The disclosure includes non-naturally occurring or engineered CRISPR systems and proteins, associated with a delivery system comprising a virus component and a lipid component. The disclosure includes CRISPR proteins associated with capsid proteins, e.g., AAV VP1VP2, and/or VP3, on the surface of or internal to the AAV, along with compositions, systems and complexes involving the AAV-CRISPR protein, nucleic acid molecules and vectors encoding the same, deliver}-systems, and uses therefor.
Type:
Grant
Filed:
April 16, 2018
Date of Patent:
July 8, 2025
Assignees:
The Broad Institute, Inc., Massachusetts Institute of Technology, Trustees of Tufts College
Abstract: Disclosed herein are fusion polypeptides comprising: (i) a fragment antigen comprising an epitope of a target protein antigen; and (ii) a complement binding polypeptide. The disclosure also provides fusion polynucleotides (e.g., mRNA) encoding the same. Also disclosed herein are methods of making and using the fusion polypeptides and fusion polynucleotides of the present disclosure.
Type:
Grant
Filed:
August 18, 2023
Date of Patent:
July 1, 2025
Assignee:
Helix Nanotechnologies Inc
Inventors:
Kyle Backman, Nikhil Dhar, Nikolai Eroshenko, Taylor Gill, Kemo Jammeh, Marianna Keaveney, Justin Quinn, Hannu Rajaniemi, Everett Webster
Abstract: The current invention relates to a purified bacterial strain for improving plant growth and/or yield. The invention also relates to a bacterial population, a microbial active ingredient, an agriculturally active ingredient, a synthetic composition, and methods for improving plant growth and/or yield by improving a trait of agronomic importance in a plant and by conferring resistance to a plant pathogen infection.
Type:
Grant
Filed:
February 10, 2020
Date of Patent:
June 24, 2025
Assignees:
APHEA.BIO NV, FUNDACIÓN CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCIA, MEDINA
Inventors:
Behnoush Ghodsalavi, Isabel Vercauteren, Steven Vandenabeele, Thomas Simon, Tom Viaene
Abstract: The present invention relates to anti-HBsAg antibodies, antibody fragments, and their uses for the prevention and treatment of hepatitis B virus infection and associated diseases.
Type:
Grant
Filed:
February 6, 2024
Date of Patent:
June 17, 2025
Assignee:
Novartis AG
Inventors:
Stefan Ewert, Meghan Marie Holdorf, Elisabetta Traggiai
Abstract: The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition. The invention also relates to antibodies to composite antigens of the invention and to methods of administering vaccines comprising antigens or vaccines of antibodies for treating and/or preventing an infection.
Type:
Grant
Filed:
December 4, 2023
Date of Patent:
June 17, 2025
Assignee:
Longhorn Vaccines and Diagnostics, LLC
Inventors:
Clara J. Sei, Luke T. Daum, Gerald W. Fischer
Abstract: The invention relates to one or more mutations configured to stabilize the prefusion “up” protomer trimeric Spike protein from SARS-CoV-2. The inventive technology further relates to systems, methods, and compositions to display one or more proteins on the surface of a yeast cell. Specifically, in one embodiment the invention relates to systems, methods, and compositions to display one or more Spike protein from SARS-CoV-2 on the surface of a yeast cell, and more preferably a Spike protein from SARS-CoV-2 stabilized in its prefusion conformation on the surface of a yeast cell.
Type:
Grant
Filed:
May 12, 2021
Date of Patent:
June 17, 2025
Assignee:
The Regents of the University of Colorado, a body corporate
Inventors:
Timothy Whitehead, Monica Kirby, Zachary Baumer, Matthew Bedewitz, Brian Petersen, Paul J. Steiner
Abstract: Disclosed herein include methods, compositions, and kits suitable for robust and tunable control of payload gene expression. Some embodiments provide rationally designed circuits, including miRNA-level and/or protein-level incoherent feed-forward loop circuits, that maintain the expression of a payload at an efficacious level. The circuit can comprise a promoter operably linked to a polynucleotide encoding a fusion protein comprising a payload protein, a protease, and one or more self-cleaving peptide sequences. The payload protein can comprise a degron and a cut site the protease is capable of cutting to expose the degron. The circuit can comprise a promoter operably linked to a polynucleotide comprising a payload gene, a silencer effector cassette, and one or more silencer effector binding sequences.
Type:
Grant
Filed:
October 4, 2023
Date of Patent:
May 13, 2025
Assignee:
California Institute of Technology
Inventors:
Michael J. Flynn, Michael B. Elowitz, Acacia Hori, Viviana Gradinaru
Abstract: The present invention provides a recombinant Vaccinia virus as a dengue virus vaccine that can be used as a therapeutic or prophylactic agent in the clinic. This recombinant Vaccinia virus is characterized by including: all or part of a cDNA that encodes a non-structural protein from a dengue virus; and an expression promoter.
Type:
Grant
Filed:
March 13, 2020
Date of Patent:
April 22, 2025
Assignees:
TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, KAGOSHIMA UNIVERSITY, NAGASAKI UNIVERSITY
Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Marburgvirus filovirus glycoprotein immunogens. Immunomodulatory methods and methods of inducing an immune response against Marburgvirus are disclosed. Method of preventing infection by Marburgvirus and methods of treating individuals infected with Marburgvirus are disclosed. Consensus Marburgvirus filovirus glycoprotein immunogens are disclosed.
Type:
Grant
Filed:
March 7, 2023
Date of Patent:
April 8, 2025
Assignees:
The Wistar Institute of Anatomy and Biology, The Trustees of the University of Pennsylvania
Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.
Type:
Grant
Filed:
April 26, 2024
Date of Patent:
April 8, 2025
Assignees:
The United States of America, as represented by the Secretary, Department of Health and Human Services, Secretary, Department of Health and Human Services
Inventors:
John R. Mascola, Jeffrey C. Boyington, Hadi M. Yassine, Peter D. Kwong, Barney S. Graham, Masaru Kanekiyo
Abstract: The invention relates to genetically encoded fusion proteins comprised of a capture component that binds a target with high affinity and a peptide polymer, such as elastin-like polypeptides, that display phase behavior and can be used for purification. The invention further relates to methods for optimizing capture fusion proteins for individual biologic targets such that phase separation occurs under desirable conditions, such as at room temperature, lower concentrations of salt, and/or at suitable pH ranges and optimized capture domains and polypeptides with phase behavior that have been identified by the optimization methods.
Abstract: Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
Type:
Grant
Filed:
May 23, 2022
Date of Patent:
March 25, 2025
Inventors:
Gale Smith, Ye Liu, Jing-Hui Tian, Michael J. Massare, Sarathi Boddapati, Erica Shane, Cynthia Oliver, Gregory Glenn
Abstract: The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Methods of using the compositions as a COVID-19 vaccine for the treatment of a coronavirus infection are also provided.
Type:
Grant
Filed:
March 21, 2024
Date of Patent:
March 25, 2025
Assignee:
HDT Bio Corp.
Inventors:
Steven Gregory Reed, Darrick Albert Carter, Amit Praful Khandhar, Jacob Freeman Archer, Lars Peter Aksel Berglund, Jesse Erasmus, Bryan Berube, Malcolm S. Duthie
Abstract: A method of non-covalently loading a plant picornavirus is described. The method includes contacting a plant picornavirus in solution with a molar excess of a cargo molecule to load the plant picornavirus with the cargo molecule, and then purifying the loaded plant picornavirus. Examples of cargo molecules include imaging agents, antitumor agents, and antiviral agents. Loaded plant picornaviruses prepared in this manner can be used to delivering cargo molecule to cells.